PD01A
Phase 1- Indications
- Parkinson's disease, Multiple System Atrophy
Company intelligence / Profile preview
AFFiRiS
Vienna, Vienna, Austriaaffiris.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 2
01
Overview
Positive Phase 1 results with immunotherapies targeting PCSK9 for hypercholesterolemia published in European Journal of Clinical Pharmacology. Positive clinical results of Phase 1 trial in early Multiple System Atrophy published in Movement Disorders Journal. Positive results of Phase 1 trial with PD01A in Parkinson's disease patients published in The Lancet Neurology.[1][5]
- Therapeutic areas
- CardiovascularNeurology
- Modalities
- Specific Active ImmunoTherapy (SAIT)immunotherapiesvaccines
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
AC ImmuneFrontier Biotechnologies
Beyond the preview
Go deeper on AFFiRiS.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AFFiRiS.